ATAI Life Sciences NV

Market Cap: Small Cap
Industry: Pharmaceuticals & Biotechnology
ISIN: NL0015000DX5

USD

4.40

0.53 (13.7%)

Dec 04

NAS

Click here to see other stocks

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Assertio Holdings, Inc.

Akebia Therapeutics, Inc.

Y-mAbs Therapeutics, Inc.

Enanta Pharmaceuticals, Inc.

ATAI Life Sciences NV

Sutro Biopharma, Inc.

Generation Bio Co.

Praxis Precision Medicines, Inc.

Immuneering Corp.

Lifecore Biomedical, Inc.

AEON Biopharma, Inc.

Why is ATAI Life Sciences NV ?

Poor Management Efficiency with a low ROE of 0%

The company has reported losses. Due to this company has reported negative ROE

Flat results in Mar 25

Risky - Negative EBITDA

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 123.81%, its profits have risen by 24.9%

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is ATAI Life Sciences NV for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

ATAI Life Sciences NV

169.94%

1.73

97.33%

S&P 500

13.22%

0.61

20.17%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

29.13%

EBIT Growth (5y)

-346.81%

EBIT to Interest (avg)

-48.62

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.54

Sales to Capital Employed (avg)

0.00

Tax Ratio

2.98%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

15.67%

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

3.18

EV to EBIT

-4.39

EV to EBITDA

-4.41

EV to Capital Employed

5.72

EV to Sales

215.20

PEG Ratio

Dividend Yield

ROCE (Latest)

-130.41%

ROE (Latest)

-63.76%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bollinger Bands

Bearish

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Mildly Bearish

Mildly Bullish

OBV

No Trend

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

1What is working for the Company

RAW MATERIAL COST(Y)

Fallen by -8,611% (YoY

0What is not working for the Company

NO KEY NEGATIVE TRIGGERS

Here's what is working for ATAI Life Sciences NV

Raw Material Cost

Fallen by -8,611% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales